We are excited to announce that Eagle IP will be participating as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Fall Conference in San Francisco. Our President and Managing Director, Ms. Jennifer Che, is a distinguished speaker at the event. Her talk, titled China Patent Landscape, will provide a brief overview of top China IP issues for life sciences companies and provide some strategies for how to navigate such issues (e.g., AI, post-filing data, PTA/PTE, patent linkage, export controls, and more).

Organized by Life Sciences Intellectual Property Review, this event will take place October 21-22, 2025.


Eagle IP will also be in the greater Washington DC area from October 27-31, 2025. Ms. Jennifer Che will be attending Life Sciences Masters™ 2025 (organized by IP Watchdog) in Ashburn, Virginia from October 27-29, and AIPLA 2025 Annual Meeting (organized by American Intellectual Property Law Association) in Washington DC from Oct 29-31.

If you won’t be able to attend LSPN or AIPLA, but will be in San Francisco or the Washington DC area and would like to schedule a meeting, please let us know. We look forward to seeing some of you in San Francisco and Washington DC later this month!

Our Past Events

Jennifer Che has been Recognized as IAM Global Leaders 2026

4 November 2025

Jennifer Che has been listed on the IAM Strategy 300

15 August 2025

Eagle IP Recognized as Top Tier Firm (Tier 1) for Patent Prosecution in IP Stars 2025 Patent Firms Ranking List

3 July 2025

Dr. Jacqueline Lui, Ms. Pauli Wong, and Mr. Eddie Ho Named Patent Stars by ManagingIP

13 June 2025

Eagle IP Ranked Among Top Tier Firms in IAM Patent 1000

12 June 2025

Jennifer Che from Eagle IP to Attend BIO 2025 in Boston!

11 June 2025

Recommended Insights

Everything you need to know about Patent Term Adjustment (PTA) in China

7 May 2024
We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
Read more >

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
Read more >

SPC Upholds $2M RMB Award in China’s First Patent Case on a Biological Deposit

4 July 2022
On 28 Feb 2022, China’s Supreme People’s Court (SPC) issued its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in 2021. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]
Read more >

The Latest on Post-Filing Data in China’s Patent Law

29 April 2020
Post-filing data can sometimes be the crucial difference between a patent allowance and a final rejection. The reasons are endless why important data may not have been included in the original patent application as filed. Time and budget may have been insufficient to generate data over the full scope of the claims at the time […]
Read more >
Top crossarrow-right